Roth Bio CEO / Investor Conference in NY,,,, Feb 9,,,,
Bio Europe Spring 2015 in Paris,,,, Mar 9
10K by Mid March,,,,
Archexin data,,,,, anytime now
RX3117 and Supinoxin data,,,, I suspect we hear that at the AACR Annual Conference in April,,,,
Archexin Nano preclinical,,, don't know
"Rexahn Pharmaceuticals Inc. has a couple of clinical-stage oncology candidates. Its most advanced compound is known as Archexin. It targets the PI3K pathway and is being studied in a Phase 2 trial for renal cell cancer. While we have not yet seen data yet from this compound, last year the FDA approved Gilead's Zydelig for lymphoma, which has a similar mechanism of action. Other large pharma companies such as Novartis and Merck & Co. Inc. (MRK:NYSE) are studying similar compounds in various oncology indications. The research synergy with these big firms could prove fruitful for Rexahn, in terms of acquisition potential.
If Rexahn can harness [recent board appointment Richard] Rodgers' experience to secure a licensing deal for Archexin, its stock price would obviously respond positively. It has a few other early-stage compounds in various tumor types. If any of these products survive later-stage studies, the market will provide rewards. We could see some Phase 1 data from Rexahn's RX-5902 and RX-3117 compounds in the near future. These are being studied for very solid tumor indications."
nice RNN mention,,,
this is the next corporate presentation,,,,
T,,,, I very much agree,,,, it's amazing to me that they felt comfortable with doubling the dose from 500 to 1000 mg,,,, btw, all of the xenograft models were based on 75 and 150mg,,,, Suzdak said that they were very excited with how the study is progressing,,,, it is certainly hard to not be impatient,,,, but I personally believe that we are in for a very pleasant surprise,,,, they would have abandoned the studies long ago if it wasn't going well,,,, the abstracts for the AACR event won't be released for review til mid March,,,, but watch for that on RX-3117 and Supinoxin,,,, as well as the ongoing studies with the Universities of Maryland and Ohio,,,, I think we will see Archexin news first,,,, I think that will come in the form of a peer reviewed journal submission,,,, so, gotta be on the look out,,,, take good care buddy,,,,
NANOPARTICULATE COMPOSITIONS AND FORMULATIONS OF PIPERAZINE COMPOUNDS
Application number: 20150004234
Abstract: The present invention relates to storage stable nanoparticulate compositions of piperazine compounds. The pharmaceutical compositions comprising the nanoparticulate compositions that are useful for the treatment and prevention of proliferative diseases including cancer are also described.
Filed: June 27, 2014
Issued: January 1, 2015
Inventors: Young Bok Lee, Chang-Ho Ahn, Deog Joong Kim
tommer,,,, suzdak said that they were in conversations with a number of oncology focused companies,,,, however, that they do not believe it prudent to enter into any serious negotiations until they have the data for these two trials,,,, he said that their leverage in the deals could increase substantially,,,,
my personal guess on the Supinoxin and RX-3117 trials is that we won't hear any news until the AACR Annual Conference in April,,,, they like to present to their peers as opposed to investor groups,,,, pretty interesting that they are now in the middle of a 1000 mg dose with RX-3117,,,, Suzdak mentioned the AACR conference as well as mentioning that they would be publishing data in peer review type publications,,,,
According to their previous statements,,,, it appears that we should hear clinical trial news on Archexin first,,,, today would be a tremendous day for that,,,,
there is a webcast,,,,
Looks like someone is getting a nice Christmas gift,,,,, Chang Ahn filed a Form 4,,,, code "G" (gift) for disposal of 803,924 shares,,,, too bad we can't see who he gave them to,,,,
Chang Ahn, Ph.D., Chairman of the Board of Directors of Rexahn added, "Rick's experience in managing oncology-focused biopharmaceutical companies spans the corporate life cycle from start-up, to building multi-billion valuations, to acquisition. We look forward to benefitting from his experience."
It appears Rexahn is presenting at the Biotech Showcase,,,, the JP Morgan Annual Healthcare Conference,,,, and listed for Trout Group's one on one sessions,,,, in San Francisco,,,, Jan 12 thru 16,,,,
would love to see med data coming thru at that time,,, but I still believe they may wait for the opportunity to present to their peers at the AACR Annual Meeting on April 18-22,,,, we will see
in any event,,,, 1Q 2015 will be interesting,,,,
In all the trials,,,, patients are signing up for the next,,,, escalated,,,, dose cycle,,,, meaning,,, that it's working.
meaning that these very sick people are able to take a drug that's working and that doesn't have the horrible side effects that the alternatives present,,,,
meaning that they want to keep taking it,,,,
meaning that they are surviving!,,,,